Literature DB >> 35277760

Development of In Vitro Dissolution Testing Methods to Simulate Fed Conditions for Immediate Release Solid Oral Dosage Forms.

Timothy R Lex1, Jason D Rodriguez1, Lei Zhang2, Wenlei Jiang3, Zongming Gao4.   

Abstract

In vitro dissolution testing is widely used to mimic and predict in vivo performance of oral drug products in the gastrointestinal (GI) tract. This literature review assesses the current in vitro dissolution methodologies being employed to simulate and predict in vivo drug dissolution under fasted and fed conditions, with emphasis on immediate release (IR) solid oral dosage forms. Notable human GI physiological conditions under fasted and fed states have been reviewed and summarized. Literature results showed that dissolution media, mechanical forces, and transit times are key dissolution test parameters for simulating specific postprandial conditions. A number of biorelevant systems, including the fed stomach model (FSM), GastroDuo device, dynamic gastric model (DGM), simulated gastrointestinal tract models (TIM), and the human gastric simulator (HGS), have been developed to mimic the postprandial state of the stomach. While these models have assisted in expanding physiological relevance of in vitro dissolution tests, in general, these models lack the ability to fully replicate physiological conditions/processes. Furthermore, the translatability of in vitro data to an in vivo system remains challenging. Additionally, physiologically based pharmacokinetic (PBPK) modeling has been employed to evaluate the effect of food on drug bioavailability and bioequivalence. Here, we assess the current status of in vitro dissolution methodologies and absorption PBPK modeling approaches to identify knowledge gaps and facilitate further development of in vitro dissolution methods that factor in fasted and fed states. Prediction of in vivo drug performance under fasted and fed conditions via in vitro dissolution testing and modeling may potentially help efforts in harmonizing global regulatory recommendations regarding in vivo fasted and fed bioequivalence studies for solid oral IR products.
© 2022. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.

Entities:  

Keywords:  bioequivalence; dissolution; fed state; in vitro model(s); oral drug; physiological model(s)

Mesh:

Year:  2022        PMID: 35277760     DOI: 10.1208/s12248-022-00690-5

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  108 in total

1.  Intragastric pH and pressure profiles after intake of the high-caloric, high-fat meal as used for food effect studies.

Authors:  M Koziolek; F Schneider; M Grimm; Chr Modeβ; A Seekamp; T Roustom; W Siegmund; W Weitschies
Journal:  J Control Release       Date:  2015-10-22       Impact factor: 9.776

2.  Draft guidance for industry extended-release solid oral dosage forms. Development, evaluation and application of in vitro-in vivo correlations.

Authors:  H Malinowski; P Marroum; V R Uppoor; W Gillespie; H Y Ahn; P Lockwood; J Henderson; R Baweja; M Hossain; N Fleischer; L Tillman; A Hussain; V Shah; A Dorantes; R Zhu; H Sun; K Kumi; S Machado; V Tammara; T E Ong-Chen; H Mahayni; L Lesko; R Williams
Journal:  Adv Exp Med Biol       Date:  1997       Impact factor: 2.622

3.  The mechanisms of pharmacokinetic food-drug interactions - A perspective from the UNGAP group.

Authors:  Mirko Koziolek; Stefano Alcaro; Patrick Augustijns; Abdul W Basit; Michael Grimm; Bart Hens; Caroline L Hoad; Philipp Jedamzik; Christine M Madla; Marc Maliepaard; Luca Marciani; Annalisa Maruca; Neil Parrott; Petr Pávek; Christopher J H Porter; Christos Reppas; Diana van Riet-Nales; Jari Rubbens; Marina Statelova; Natalie L Trevaskis; Kateřina Valentová; Maria Vertzoni; Dubravka Vitali Čepo; Maura Corsetti
Journal:  Eur J Pharm Sci       Date:  2019-04-08       Impact factor: 4.384

4.  Impact of regional differences along the gastrointestinal tract of healthy adults on oral drug absorption: An UNGAP review.

Authors:  Maria Vertzoni; Patrick Augustijns; Michael Grimm; Mirko Koziolek; Glenn Lemmens; Neil Parrott; Christina Pentafragka; Christos Reppas; Jari Rubbens; Jens Van Den Αbeele; Tim Vanuytsel; Werner Weitschies; Clive G Wilson
Journal:  Eur J Pharm Sci       Date:  2019-04-13       Impact factor: 4.384

Review 5.  Food for thought: formulating away the food effect - a PEARRL review.

Authors:  Joseph P O'Shea; René Holm; Caitriona M O'Driscoll; Brendan T Griffin
Journal:  J Pharm Pharmacol       Date:  2018-06-28       Impact factor: 3.765

Review 6.  Simulating the postprandial stomach: physiological considerations for dissolution and release testing.

Authors:  Mirko Koziolek; Grzegorz Garbacz; Marco Neumann; Werner Weitschies
Journal:  Mol Pharm       Date:  2013-04-01       Impact factor: 4.939

7.  Intragastric volume changes after intake of a high-caloric, high-fat standard breakfast in healthy human subjects investigated by MRI.

Authors:  Mirko Koziolek; Michael Grimm; Grzegorz Garbacz; Jens-Peter Kühn; Werner Weitschies
Journal:  Mol Pharm       Date:  2014-04-15       Impact factor: 4.939

Review 8.  The Global Bioequivalence Harmonization Initiative: Summary report for EUFEPS international conference.

Authors:  Mei-Ling Chen; Henning Blume; Gerald Beuerle; Barbara Davit; Mehul Mehta; Henrike Potthast; Barbara Schug; Yu Chung Tsang; Ralph-Steven Wedemeyer; Werner Weitschies; Jan Welink
Journal:  Eur J Pharm Sci       Date:  2017-09-28       Impact factor: 4.384

9.  Application of the GastroDuo as an in Vitro Dissolution Tool To Simulate the Gastric Emptying of the Postprandial Stomach.

Authors:  Philipp Schick; Maximilian Sager; Franziska Wegner; Markus Wiedmann; Elisabeth Schapperer; Werner Weitschies; Mirko Koziolek
Journal:  Mol Pharm       Date:  2019-10-22       Impact factor: 4.939

Review 10.  Physiological parameters for oral delivery and in vitro testing.

Authors:  Deanna M Mudie; Gordon L Amidon; Gregory E Amidon
Journal:  Mol Pharm       Date:  2010-09-07       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.